Citius Pharmaceuticals’ (CTXR) Buy Rating Reaffirmed at D. Boral Capital

Citius Pharmaceuticals (NASDAQ:CTXR)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $6.00 price target on the stock. D. Boral Capital’s price objective points to a potential upside of 385.83% from the stock’s previous close.

Other research analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Monday. Wall Street Zen downgraded Citius Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, September 26th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $6.00.

Citius Pharmaceuticals Trading Up 7.9%

CTXR stock traded up $0.09 during midday trading on Thursday, reaching $1.24. The stock had a trading volume of 353,648 shares, compared to its average volume of 1,058,728. Citius Pharmaceuticals has a 52-week low of $0.65 and a 52-week high of $5.95. The company’s fifty day simple moving average is $1.33 and its 200 day simple moving average is $1.28. The company has a market cap of $21.01 million, a price-to-earnings ratio of -0.37 and a beta of 1.51.

Hedge Funds Weigh In On Citius Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC acquired a new position in Citius Pharmaceuticals in the 2nd quarter valued at about $40,000. XTX Topco Ltd acquired a new position in shares of Citius Pharmaceuticals in the second quarter valued at approximately $32,000. Finally, Arkadios Wealth Advisors increased its stake in Citius Pharmaceuticals by 100.0% during the 2nd quarter. Arkadios Wealth Advisors now owns 20,000 shares of the company’s stock worth $32,000 after buying an additional 10,000 shares during the period. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.